Compared to Estimates, Elevance Health (ELV) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for Elevance Health (ELV) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Elevance Health's Q3 Earnings: Profit Falls Short Of Expectations On Higher Medical Costs, Issues Soft Annual Outlook
On Thursday, Elevance Health Inc. ELV reported third-quarter revenues of $44.7 billion, up 5.3% year-over-year, beating the consensus of $43.33 billion.
Elevance Health (ELV) Q3 Earnings Lag Estimates
Elevance Health (ELV) came out with quarterly earnings of $8.37 per share, missing the Zacks Consensus Estimate of $9.70 per share. This compares to earnings of $8.99 per share a year ago.
Elevance Health's stock tumbles as profit dented by ‘unprecedented' Medicaid challenges
“We remain confident in the long-term earnings potential of our diverse businesses as we navigate a dynamic operating environment and unprecedented challenges in the Medicaid business,” Chief Executive Gail K. Boudreaux said in prepared remarks.
Elevance Health cuts annual profit forecast on persistently higher medical costs
Elevance Health cut its full-year profit forecast on Thursday, as it expects to pay out more in claims due to robust demand for medical care from members in its government-backed plans, sending its shares down 6% in premarket trading.
Will Elevance Health (ELV) Beat Estimates Again in Its Next Earnings Report?
Elevance Health (ELV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Elevance's Pre-Q3 Earnings Analysis: Smart Buy Now or Caution Ahead?
ELV's third-quarter results are likely to reflect growing operating income from the Carelon business.
Gear Up for Elevance Health (ELV) Q3 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Elevance Health (ELV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
Elevance: Our Top Value Pick Trading At 12.5x Earnings And Growing At 12.5%
Elevance is a high-quality compounder with consistent EPS growth, trading at a significant discount to peers like UnitedHealth, presenting an attractive entry point. Despite recent stock dips due to minor issues, Elevance's solid management, investment-grade balance sheet, and demographic tailwinds make it a lower-risk investment. Medicaid and Medicare Advantage concerns are manageable, with potential EPS impacts already factored into the current stock price.
Elevance Health (ELV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Elevance Health (ELV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Add Elevance Health Stock to Your Portfolio
ELV benefits from an increase in employer group fee-based memberships, partially offsetting the impact of Medicaid memberships.
Elevance Health Stock Has More to Offer: Should You Hold on Tight?
In the commercial category, an increase in individual as well as employer group fee-based memberships will continue supporting ELV's medical membership numbers.
